Supernus Pharmaceuticals (SUPN) Interest Coverage Ratio Growth (1y) (2012 - 2026)
Supernus Pharmaceuticals (SUPN) Interest Coverage Ratio Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -83.16% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 128.45% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -97.39% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -8.29% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -144.96% |
| Dec 31, 2025 | -94.82% |
| Sep 30, 2025 | -443.01% |
| Jun 30, 2025 | 920.62% |
| Mar 31, 2025 | -234.47% |
| Dec 31, 2024 | 348.32% |
| Jun 30, 2024 | 128.23% |
| Mar 31, 2024 | -152.62% |
| Dec 31, 2023 | -164.12% |
| Jun 30, 2023 | -12,858.20% |
| Mar 31, 2023 | 5,608.89% |
| Dec 31, 2022 | 222.28% |
| Sep 30, 2022 | -77.61% |
| Jun 30, 2022 | -97.57% |
| Mar 31, 2022 | -98.79% |
| Dec 31, 2021 | -85.43% |
| Sep 30, 2021 | -40.33% |
| Mar 31, 2021 | -57.01% |
| Dec 31, 2020 | 248.92% |
| Sep 30, 2020 | 31.42% |